Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation

Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We d...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Miller, Rachael, Paquette, Joseph, Barker, Alexandra, Sapp, Ellen, McHugh, Nicholas, Bramato, Brianna, Yamada, Nozomi, Alterman, Julia, Echeveria, Dimas, Yamada, Ken, Watts, Jonathan, Anaclet, Christelle, DiFiglia, Marian, Khvorova, Anastasia, Aronin, Neil
Format Journal Article Paper
LanguageEnglish
Published Cold Spring Harbor Laboratory 08.06.2024
Edition1.1
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.
AbstractList Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.
Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.
Author Echeveria, Dimas
Barker, Alexandra
Paquette, Joseph
Bramato, Brianna
Yamada, Nozomi
Anaclet, Christelle
McHugh, Nicholas
Sapp, Ellen
Miller, Rachael
Watts, Jonathan
Khvorova, Anastasia
Yamada, Ken
Aronin, Neil
Alterman, Julia
DiFiglia, Marian
Author_xml – sequence: 1
  givenname: Rachael
  surname: Miller
  fullname: Miller, Rachael
– sequence: 2
  givenname: Joseph
  surname: Paquette
  fullname: Paquette, Joseph
– sequence: 3
  givenname: Alexandra
  surname: Barker
  fullname: Barker, Alexandra
– sequence: 4
  givenname: Ellen
  surname: Sapp
  fullname: Sapp, Ellen
– sequence: 5
  givenname: Nicholas
  surname: McHugh
  fullname: McHugh, Nicholas
– sequence: 6
  givenname: Brianna
  surname: Bramato
  fullname: Bramato, Brianna
– sequence: 7
  givenname: Nozomi
  surname: Yamada
  fullname: Yamada, Nozomi
– sequence: 8
  givenname: Julia
  surname: Alterman
  fullname: Alterman, Julia
– sequence: 9
  givenname: Dimas
  surname: Echeveria
  fullname: Echeveria, Dimas
– sequence: 10
  givenname: Ken
  surname: Yamada
  fullname: Yamada, Ken
– sequence: 11
  givenname: Jonathan
  surname: Watts
  fullname: Watts, Jonathan
– sequence: 12
  givenname: Christelle
  surname: Anaclet
  fullname: Anaclet, Christelle
– sequence: 13
  givenname: Marian
  surname: DiFiglia
  fullname: DiFiglia, Marian
– sequence: 14
  givenname: Anastasia
  surname: Khvorova
  fullname: Khvorova, Anastasia
– sequence: 15
  givenname: Neil
  surname: Aronin
  fullname: Aronin, Neil
BookMark eNpNkEtLAzEUhYNUsNb-AHdZCjI1j5mkWUrxBfUB6nrIJHfayDSpmUxt_70dKygcuGfxnbv4TtHABw8InVMyoZTQK0ZYPiGiT6Gk4OoIDZlQLJsyUgz-9RM0btsPQghTgnKZD9H2JcIGfHJ-gbXpEmAPXQwpbJ1xaYdDjWdPrzgtIeo1dMkZHBq3CL4zDYTkLLT4y6VlT2BtrUsu-J-VZpdYe4sfF_vi_A9Qh7jqGt0zZ-i41k0L4987Qu-3N2-z-2z-fPcwu55nFRWFyqAoaG4Uq1ieSwJQF7aqKa9UzbkBaqSlhlQVlZJUBCwtFFdWai0EB6v30AhdHP5WLsSt25Tr6FY67speWklEn4O0P3Qdw2cHbSpXrjXQNNpD6NqSE0mme3WM8G90bXD9
Cites_doi 10.1016/j.omtn.2019.11.020
10.1089/nat.2023.0068
10.1093/nar/gku142
10.1093/nar/gkab1126
10.1021/mp200250f
10.1089/nat.2021.0071
10.1038/s41467-022-33061-x
10.1038/ncomms9744
10.1113/jphysiol.1958.sp006022
10.1016/j.jhep.2023.06.013
10.1093/nar/gkaa595
10.1172/jci99081
10.1038/mtna.2016.50
10.1085/jgp.82.6.785
10.1016/0896-6273(95)90346-1
10.1172/jci.insight.152203
10.1002/cmdc.201000156
10.1093/nar/gkad067
10.1111/j.1471-4159.1986.tb13082.x
10.3233/jhd-229003
10.1089/108729003321629638
10.1056/NEJMoa1900907
10.1038/nn.3789
10.1056/NEJMc2300400
10.1038/s41587-022-01334-x
10.1261/rna.060079.116
10.1016/j.omtn.2022.12.010
10.1016/j.ymthe.2023.05.006
10.1093/nar/gkz771
10.1093/hmg/ddg169
10.1093/nar/gkaa299
10.1101/2021.02.14.431096
10.1021/bi982201
10.1093/nar/gky060
10.1146/annurev.pharmtox.010909.105654
10.1006/jmbi.1997.1383
10.1101/2023.05.26.542506
10.1038/nbt.3765
10.1016/j.neuron.2022.01.006
10.1016/j.omtn.2017.07.003
10.1089/nat.2023.0027
10.1126/science.aba4624
10.1038/d41573-023-00001-3
10.1016/j.bpj.2019.08.007
10.1523/jneurosci.2955-17.2018
10.1093/nar/gkg147
10.1038/npp.2017.152
10.1038/nrdp.2015.5
10.1038/s41587-019-0205-0
10.3233/jhd-239001
10.1038/s41573-021-00162-z
10.1056/NEJMoa1702752
10.1016/0143-4160(83)90047-7
10.1089/nat.2014.0506
10.1056/NEJMoa2204705
10.1113/jphysiol.1957.sp005808
10.1146/annurev-biochem-060409-092720
10.1038/s41573-024-00912-9
10.1261/rna.5205404
10.1016/j.neuron.2016.02.003
10.3389/fnins.2019.00755
10.1089/nat.2020.0923
10.1016/j.ymthe.2018.03.019
10.1016/j.celrep.2018.07.106
10.1177/1759091415578050
10.1002/mds.26020
10.3390/jcm9062004
ContentType Journal Article
Paper
Copyright 2024, Posted by Cold Spring Harbor Laboratory
Copyright_xml – notice: 2024, Posted by Cold Spring Harbor Laboratory
DBID 7X8
FX.
DOI 10.1101/2024.06.06.597639
DatabaseName MEDLINE - Academic
bioRxiv
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Database_xml – sequence: 1
  dbid: FX.
  name: bioRxiv
  url: https://www.biorxiv.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2692-8205
Edition 1.1
ExternalDocumentID 2024.06.06.597639v1
GroupedDBID 7X8
8FE
8FH
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
CCPQU
HCIFZ
LK8
M7P
NQS
PHGZM
PHGZT
PIMPY
PROAC
RHI
FX.
ID FETCH-LOGICAL-b1659-e5514c92b24470eef5dbf13b9f33ce1c7d1c0bb1770b0ed15939d7aa663edaf33
IEDL.DBID FX.
ISSN 2692-8205
IngestDate Tue Jan 07 18:58:16 EST 2025
Fri Jul 11 07:25:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
License This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b1659-e5514c92b24470eef5dbf13b9f33ce1c7d1c0bb1770b0ed15939d7aa663edaf33
Notes ObjectType-Working Paper/Pre-Print-3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interest Statement: AK and NA are co-founders, on the scientific advisory board, and hold equities of Atalanta Therapeutics; AK is a founder of Comanche Pharmaceuticals and on the scientific advisory board of Aldena Therapeutics, AlltRNA, Prime Medicine, and EVOX Therapeutics; NA is on the scientific advisory board of Huntington's Disease Society of America (HDSA); Select authors hold patents or patent applications relating to the divalent siRNA and the methods described in this report.
ORCID 0000-0001-6966-7696
0000-0002-6195-0857
0000-0002-4594-0640
0000-0002-0526-8132
0000-0002-5714-8298
0000-0001-6928-8071
0000-0001-5706-1734
OpenAccessLink https://www.biorxiv.org/content/10.1101/2024.06.06.597639
PQID 3070802920
PQPubID 23479
PageCount 50
ParticipantIDs biorxiv_primary_2024_06_06_597639
proquest_miscellaneous_3070802920
PublicationCentury 2000
PublicationDate 20240608
PublicationDateYYYYMMDD 2024-06-08
PublicationDate_xml – month: 06
  year: 2024
  text: 20240608
  day: 08
PublicationDecade 2020
PublicationTitle bioRxiv
PublicationYear 2024
Publisher Cold Spring Harbor Laboratory
Publisher_xml – name: Cold Spring Harbor Laboratory
References Finkel (2024.06.06.597639v1.3) 2017; 377
Mullard (2024.06.06.597639v1.7) 2023; 22
Tabrizi (2024.06.06.597639v1.28) 2019; 380
Harborth (2024.06.06.597639v1.46) 2003; 13
van Roon-Mom, Ferguson, Aartsma-Rus (2024.06.06.597639v1.4) 2023; 33
Crooke, Baker, Crooke, Liang (2024.06.06.597639v1.66) 2021; 20
Dhuri (2024.06.06.597639v1.8) 2020; 9
Frankenhaeuser, Meves (2024.06.06.597639v1.57) 1958; 142
Jia (2024.06.06.597639v1.15) 2023; 31
Anaclet (2024.06.06.597639v1.39) 2015; 6
Yamada (2024.06.06.597639v1.53) 2021; 49
Khvorova, Watts (2024.06.06.597639v1.52) 2017; 35
Leavitt, Tabrizi (2024.06.06.597639v1.32) 2020; 367
Hagedorn (2024.06.06.597639v1.16) 2022; 32
Alterman (2024.06.06.597639v1.12) 2019; 37
Gu (2024.06.06.597639v1.68) 2022; 110
Kamola (2024.06.06.597639v1.47) 2017; 8
Ferguson (2024.06.06.597639v1.13) 2021; 6
Bukhman, Draper (2024.06.06.597639v1.24) 1997; 273
Bates (2024.06.06.597639v1.29) 2015; 1
Durham (2024.06.06.597639v1.60) 1983; 4
Bennett, Swayze (2024.06.06.597639v1.9) 2010; 50
Nikan (2024.06.06.597639v1.27) 2016; 5
Crooke, Vickers, Liang (2024.06.06.597639v1.62) 2020; 48
Moazami (2024.06.06.597639v1.19) 2021
Slow (2024.06.06.597639v1.67) 2003; 12
Keith, Franklin (2024.06.06.597639v1.70) 2008
Aronin, DiFiglia (2024.06.06.597639v1.31) 2014; 29
Papaioannou, Fox (2024.06.06.597639v1.33) 1993; 43
Egli, Manoharan (2024.06.06.597639v1.1) 2023; 51
Conroy (2024.06.06.597639v1.35) 2022; 13
Han, Trinidad, Shi (2024.06.06.597639v1.59) 2015; 7
Brown (2024.06.06.597639v1.11) 2022; 40
Didiot (2024.06.06.597639v1.43) 2018; 24
Cunha, Bussi (2024.06.06.597639v1.51) 2017; 23
McColgan (2024.06.06.597639v1.6) 2023; 389
O’Reilly (2024.06.06.597639v1.61) 2023; 31
Miller (2024.06.06.597639v1.5) 2022; 387
Vickers, Rahdar, Prakash, Crooke (2024.06.06.597639v1.63) 2019; 47
Biscans (2024.06.06.597639v1.25) 2018; 26
Biscans (2024.06.06.597639v1.26) 2020; 48
Saudou, Humbert (2024.06.06.597639v1.30) 2016; 89
Murphy, Smith, Rapoport (2024.06.06.597639v1.41) 1986; 47
Kuter (2024.06.06.597639v1.2) 2023; 79
Erickson, Ferrari, Gompf, Anaclet (2024.06.06.597639v1.40) 2019; 13
Lipfert, Doniach, Das, Herschlag (2024.06.06.597639v1.20) 2014; 83
Aronin (2024.06.06.597639v1.18) 2022; 11
Anaclet (2024.06.06.597639v1.37) 2014; 17
Gebala, Herschlag (2024.06.06.597639v1.21) 2019; 117
Eckstein (2024.06.06.597639v1.44) 2014; 24
Liang (2024.06.06.597639v1.65) 2021; 31
Shen (2024.06.06.597639v1.50) 2018; 46
Estevez-Fraga, Tabrizi, Wild (2024.06.06.597639v1.17) 2023; 12
Frankenhaeuser, Hodgkin (2024.06.06.597639v1.56) 1957; 137
Tang, Khvorova (2024.06.06.597639v1.55) 2024; 23
Paxinos, Franklin (2024.06.06.597639v1.69) 2001; 2
Burdick (2024.06.06.597639v1.48) 2014; 42
Yamada (2024.06.06.597639v1.34) 2023
DiFiglia (2024.06.06.597639v1.71) 1995; 14
McFail-Isom, Shui, Williams (2024.06.06.597639v1.23) 1998; 37
Kubo (2024.06.06.597639v1.10) 2011; 8
Anaclet, Griffith, Fuller (2024.06.06.597639v1.38) 2018; 43
Aupy (2024.06.06.597639v1.64) 2020; 19
Draper (2024.06.06.597639v1.22) 2004; 10
Winkler, Stessl, Amartey, Noe (2024.06.06.597639v1.49) 2010; 5
Hahin, Campbell (2024.06.06.597639v1.58) 1983; 82
McCampbell (2024.06.06.597639v1.14) 2018; 128
Anaclet (2024.06.06.597639v1.36) 2018; 38
Harris, Sonnenblick (2024.06.06.597639v1.42) 1955; 27
Amarzguioui, Holen, Babaie, Prydz (2024.06.06.597639v1.45) 2003; 31
Belgrad, Fakih, Khvorova (2024.06.06.597639v1.54) 2024
References_xml – volume: 19
  start-page: 371
  year: 2020
  end-page: 383
  ident: 2024.06.06.597639v1.64
  article-title: Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2019.11.020
– year: 2024
  ident: 2024.06.06.597639v1.54
  article-title: Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2023.0068
– volume: 42
  start-page: 4882
  year: 2014
  end-page: 4891
  ident: 2024.06.06.597639v1.48
  article-title: Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku142
– volume: 49
  start-page: 12069
  year: 2021
  end-page: 12088
  ident: 2024.06.06.597639v1.53
  article-title: Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkab1126
– volume: 8
  start-page: 2193
  year: 2011
  end-page: 2203
  ident: 2024.06.06.597639v1.10
  article-title: Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity
  publication-title: Mol Pharm
  doi: 10.1021/mp200250f
– volume: 32
  start-page: 151
  year: 2022
  end-page: 162
  ident: 2024.06.06.597639v1.16
  article-title: Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2021.0071
– volume: 13
  start-page: 5802
  year: 2022
  ident: 2024.06.06.597639v1.35
  article-title: Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-33061-x
– volume: 6
  start-page: 8744
  year: 2015
  ident: 2024.06.06.597639v1.39
  article-title: Basal forebrain control of wakefulness and cortical rhythms
  publication-title: Nat Commun
  doi: 10.1038/ncomms9744
– volume: 142
  start-page: 360
  year: 1958
  end-page: 365
  ident: 2024.06.06.597639v1.57
  article-title: The effect of magnesium and calcium on the frog myelinated nerve fibre
  publication-title: J Physiol
  doi: 10.1113/jphysiol.1958.sp006022
– volume: 79
  start-page: 1150
  year: 2023
  end-page: 1158
  ident: 2024.06.06.597639v1.2
  article-title: Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2023.06.013
– volume: 48
  start-page: 7665
  year: 2020
  end-page: 7680
  ident: 2024.06.06.597639v1.26
  article-title: The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa595
– volume: 128
  start-page: 3558
  year: 2018
  end-page: 3567
  ident: 2024.06.06.597639v1.14
  article-title: Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
  publication-title: J Clin Invest
  doi: 10.1172/jci99081
– volume: 5
  start-page: e344
  year: 2016
  ident: 2024.06.06.597639v1.27
  article-title: Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1038/mtna.2016.50
– volume: 82
  start-page: 785
  year: 1983
  end-page: 805
  ident: 2024.06.06.597639v1.58
  article-title: Simple shifts in the voltage dependence of sodium channel gating caused by divalent cations
  publication-title: J Gen Physiol
  doi: 10.1085/jgp.82.6.785
– volume: 14
  start-page: 1075
  year: 1995
  end-page: 1081
  ident: 2024.06.06.597639v1.71
  article-title: Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
  publication-title: Neuron
  doi: 10.1016/0896-6273(95)90346-1
– volume: 6
  year: 2021
  ident: 2024.06.06.597639v1.13
  article-title: Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.152203
– volume: 5
  start-page: 1344
  year: 2010
  end-page: 1352
  ident: 2024.06.06.597639v1.49
  article-title: Off-target effects related to the phosphorothioate modification of nucleic acids
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.201000156
– volume: 51
  start-page: 2529
  year: 2023
  end-page: 2573
  ident: 2024.06.06.597639v1.1
  article-title: Chemistry, structure and function of approved oligonucleotide therapeutics
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkad067
– volume: 47
  start-page: 1735
  year: 1986
  end-page: 1741
  ident: 2024.06.06.597639v1.41
  article-title: Homeostasis of brain and cerebrospinal fluid calcium concentrations during chronic hypo- and hypercalcemia
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.1986.tb13082.x
– volume: 11
  start-page: 119
  year: 2022
  end-page: 120
  ident: 2024.06.06.597639v1.18
  article-title: Perspective: Tominersen Testing Finds a Way Forward
  publication-title: J Huntingtons Dis
  doi: 10.3233/jhd-229003
– volume: 13
  start-page: 83
  year: 2003
  end-page: 105
  ident: 2024.06.06.597639v1.46
  article-title: Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing
  publication-title: Antisense Nucleic Acid Drug Dev
  doi: 10.1089/108729003321629638
– volume: 380
  start-page: 2307
  year: 2019
  end-page: 2316
  ident: 2024.06.06.597639v1.28
  article-title: Targeting Huntingtin Expression in Patients with Huntington’s Disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1900907
– volume: 17
  start-page: 1217
  year: 2014
  end-page: 1224
  ident: 2024.06.06.597639v1.37
  article-title: The GABAergic parafacial zone is a medullary slow wave sleep-promoting center
  publication-title: Nat Neurosci
  doi: 10.1038/nn.3789
– volume: 2
  year: 2001
  ident: 2024.06.06.597639v1.69
– volume: 389
  start-page: 2203
  year: 2023
  end-page: 2205
  ident: 2024.06.06.597639v1.6
  article-title: Tominersen in Adults with Manifest Huntington’s Disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2300400
– volume: 40
  start-page: 1500
  year: 2022
  end-page: 1508
  ident: 2024.06.06.597639v1.11
  article-title: Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates
  publication-title: Nat Biotechnol
  doi: 10.1038/s41587-022-01334-x
– volume: 23
  start-page: 628
  year: 2017
  end-page: 638
  ident: 2024.06.06.597639v1.51
  article-title: Unraveling Mg(2+)-RNA binding with atomistic molecular dynamics
  publication-title: Rna
  doi: 10.1261/rna.060079.116
– volume: 31
  start-page: 182
  year: 2023
  end-page: 196
  ident: 2024.06.06.597639v1.15
  article-title: Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2022.12.010
– volume: 31
  start-page: 1661
  year: 2023
  end-page: 1674
  ident: 2024.06.06.597639v1.61
  article-title: Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington’s disease
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2023.05.006
– volume: 47
  start-page: 10865
  year: 2019
  end-page: 10880
  ident: 2024.06.06.597639v1.63
  article-title: Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkz771
– volume: 12
  start-page: 1555
  year: 2003
  end-page: 1567
  ident: 2024.06.06.597639v1.67
  article-title: Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddg169
– volume: 48
  start-page: 5235
  year: 2020
  end-page: 5253
  ident: 2024.06.06.597639v1.62
  article-title: Phosphorothioate modified oligonucleotide-protein interactions
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa299
– year: 2021
  ident: 2024.06.06.597639v1.19
  article-title: Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System
  publication-title: bioRxiv
  doi: 10.1101/2021.02.14.431096
– volume: 37
  start-page: 17105
  year: 1998
  end-page: 17111
  ident: 2024.06.06.597639v1.23
  article-title: Divalent cations stabilize unstacked conformations of DNA and RNA by interacting with base pi systems
  publication-title: Biochemistry
  doi: 10.1021/bi982201
– volume: 46
  start-page: 2204
  year: 2018
  end-page: 2217
  ident: 2024.06.06.597639v1.50
  article-title: Acute hepatotoxicity of 2’ fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky060
– volume: 50
  start-page: 259
  year: 2010
  end-page: 293
  ident: 2024.06.06.597639v1.9
  article-title: RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev.pharmtox.010909.105654
– volume: 43
  start-page: 189
  year: 1993
  end-page: 192
  ident: 2024.06.06.597639v1.33
  article-title: Efficacy of tribromoethanol anesthesia in mice
  publication-title: Lab Anim Sci
– volume: 273
  start-page: 1020
  year: 1997
  end-page: 1031
  ident: 2024.06.06.597639v1.24
  article-title: Affinities and selectivities of divalent cation binding sites within an RNA tertiary structure
  publication-title: J Mol Biol
  doi: 10.1006/jmbi.1997.1383
– year: 2023
  ident: 2024.06.06.597639v1.34
  article-title: Extended Nucleic Acid (exNA): A Novel
  publication-title: Biologically Compatible Backbone that Significantly Enhances Oligonucleotide Efficacy in vivo. bioRxiv
  doi: 10.1101/2023.05.26.542506
– volume: 35
  start-page: 238
  year: 2017
  end-page: 248
  ident: 2024.06.06.597639v1.52
  article-title: The chemical evolution of oligonucleotide therapies of clinical utility
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3765
– volume: 110
  start-page: 1173
  year: 2022
  end-page: 1192
  ident: 2024.06.06.597639v1.68
  article-title: Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice
  publication-title: Neuron
  doi: 10.1016/j.neuron.2022.01.006
– volume: 8
  start-page: 383
  year: 2017
  end-page: 394
  ident: 2024.06.06.597639v1.47
  article-title: Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2017.07.003
– volume: 33
  start-page: 234
  year: 2023
  end-page: 237
  ident: 2024.06.06.597639v1.4
  article-title: From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2023.0027
– volume: 367
  start-page: 1428
  year: 2020
  end-page: 1429
  ident: 2024.06.06.597639v1.32
  article-title: Antisense oligonucleotides for neurodegeneration
  publication-title: Science
  doi: 10.1126/science.aba4624
– volume: 22
  start-page: 83
  year: 2023
  end-page: 88
  ident: 2024.06.06.597639v1.7
  article-title: 2022 FDA approvals
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/d41573-023-00001-3
– volume: 117
  start-page: 1116
  year: 2019
  end-page: 1124
  ident: 2024.06.06.597639v1.21
  article-title: Quantitative Studies of an RNA Duplex Electrostatics by Ion Counting
  publication-title: Biophys J
  doi: 10.1016/j.bpj.2019.08.007
– volume: 38
  start-page: 5168
  year: 2018
  end-page: 5181
  ident: 2024.06.06.597639v1.36
  article-title: Genetic Activation, Inactivation, and Deletion Reveal a Limited And Nuanced Role for Somatostatin-Containing Basal Forebrain Neurons in Behavioral State Control
  publication-title: J Neurosci
  doi: 10.1523/jneurosci.2955-17.2018
– volume: 31
  start-page: 589
  year: 2003
  end-page: 595
  ident: 2024.06.06.597639v1.45
  article-title: Tolerance for mutations and chemical modifications in a siRNA
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkg147
– volume: 43
  start-page: 415
  year: 2018
  end-page: 425
  ident: 2024.06.06.597639v1.38
  article-title: Activation of the GABAergic Parafacial Zone Maintains Sleep and Counteracts the Wake-Promoting Action of the Psychostimulants Armodafinil and Caffeine
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2017.152
– volume: 1
  start-page: 15005
  year: 2015
  ident: 2024.06.06.597639v1.29
  article-title: Huntington disease
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/nrdp.2015.5
– volume: 37
  start-page: 884
  year: 2019
  end-page: 894
  ident: 2024.06.06.597639v1.12
  article-title: A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system
  publication-title: Nat Biotechnol
  doi: 10.1038/s41587-019-0205-0
– volume: 12
  start-page: 169
  year: 2023
  end-page: 185
  ident: 2024.06.06.597639v1.17
  article-title: Huntington’s Disease Clinical Trials Corner: August 2023
  publication-title: J Huntingtons Dis
  doi: 10.3233/jhd-239001
– volume: 20
  start-page: 427
  year: 2021
  end-page: 453
  ident: 2024.06.06.597639v1.66
  article-title: Antisense technology: an overview and prospectus
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00162-z
– volume: 377
  start-page: 1723
  year: 2017
  end-page: 1732
  ident: 2024.06.06.597639v1.3
  article-title: Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1702752
– volume: 4
  start-page: 33
  year: 1983
  end-page: 46
  ident: 2024.06.06.597639v1.60
  article-title: A survey of readily available chelators for buffering calcium ion concentrations in physiological solutions
  publication-title: Cell Calcium
  doi: 10.1016/0143-4160(83)90047-7
– volume: 24
  start-page: 374
  year: 2014
  end-page: 387
  ident: 2024.06.06.597639v1.44
  article-title: Phosphorothioates, essential components of therapeutic oligonucleotides
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2014.0506
– volume: 387
  start-page: 1099
  year: 2022
  end-page: 1110
  ident: 2024.06.06.597639v1.5
  article-title: Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2204705
– volume: 27
  start-page: 297
  year: 1955
  end-page: 303
  ident: 2024.06.06.597639v1.42
  article-title: A study of calcium and magnesium in the cerebrospinal fluid
  publication-title: Yale J Biol Med
– volume: 137
  start-page: 218
  year: 1957
  end-page: 244
  ident: 2024.06.06.597639v1.56
  article-title: The action of calcium on the electrical properties of squid axons
  publication-title: J Physiol
  doi: 10.1113/jphysiol.1957.sp005808
– volume: 83
  start-page: 813
  year: 2014
  end-page: 841
  ident: 2024.06.06.597639v1.20
  article-title: Understanding nucleic acid-ion interactions
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev-biochem-060409-092720
– volume: 23
  start-page: 341
  year: 2024
  end-page: 364
  ident: 2024.06.06.597639v1.55
  article-title: RNAi-based drug design: considerations and future directions
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-024-00912-9
– volume: 10
  start-page: 335
  year: 2004
  end-page: 343
  ident: 2024.06.06.597639v1.22
  article-title: A guide to ions and RNA structure
  publication-title: Rna
  doi: 10.1261/rna.5205404
– volume: 89
  start-page: 910
  year: 2016
  end-page: 926
  ident: 2024.06.06.597639v1.30
  article-title: The Biology of Huntingtin
  publication-title: Neuron
  doi: 10.1016/j.neuron.2016.02.003
– year: 2008
  ident: 2024.06.06.597639v1.70
– volume: 13
  start-page: 755
  year: 2019
  ident: 2024.06.06.597639v1.40
  article-title: Differential Role of Pontomedullary Glutamatergic Neuronal Populations in Sleep-Wake Control
  publication-title: Front Neurosci
  doi: 10.3389/fnins.2019.00755
– volume: 31
  start-page: 126
  year: 2021
  end-page: 144
  ident: 2024.06.06.597639v1.65
  article-title: Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2020.0923
– volume: 26
  start-page: 1520
  year: 2018
  end-page: 1528
  ident: 2024.06.06.597639v1.25
  article-title: Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2018.03.019
– volume: 24
  start-page: 2553
  year: 2018
  end-page: 2560.e2555
  ident: 2024.06.06.597639v1.43
  article-title: Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2018.07.106
– volume: 7
  year: 2015
  ident: 2024.06.06.597639v1.59
  article-title: Hypocalcemia-induced seizure: demystifying the calcium paradox
  publication-title: ASN Neuro
  doi: 10.1177/1759091415578050
– volume: 29
  start-page: 1455
  year: 2014
  end-page: 1461
  ident: 2024.06.06.597639v1.31
  article-title: Huntingtin-lowering strategies in Huntington’s disease: antisense oligonucleotides, small RNAs, and gene editing
  publication-title: Mov Disord
  doi: 10.1002/mds.26020
– volume: 9
  year: 2020
  ident: 2024.06.06.597639v1.8
  article-title: Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
  publication-title: J Clin Med
  doi: 10.3390/jcm9062004
SSID ssj0002961374
Score 1.8752766
SecondaryResourceType preprint
Snippet Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs...
SourceID biorxiv
proquest
SourceType Open Access Repository
Aggregation Database
SubjectTerms Neuroscience
Title Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
URI https://www.proquest.com/docview/3070802920
https://www.biorxiv.org/content/10.1101/2024.06.06.597639
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La8MwDDZby2C3PdmzeLDbSHGap68rLWXQUrYVegt-KCUwktKmo_v3k5J0FLbDbiHICUi29NmSPzH2CIg5CEk7Itbg-L4ER0aedLTuGaWtjkHT3eHxJBzN_Jd5MN9r9UVllTorVtvss8rjU8E2et96cQuX9up-RbgZdhEKY3g9ZG2cUj6tyeG8-3O80pMYpyK_yWP-ORIRb_OnX364Ci7DE9aeqiWsTtkB5GfsqO4O-XXOtjt6pXzBldmUwCvyybLYZgaxMy9S3p-88b0bVLz4yBZFThTFRZlZWHM6ZiUJTnVDZINqlOo9cZVbPl7gQ5ZXAgRem1ZeF2w2HLz3R07TKMHRbhhIBwj2GNnTGKsjAZAGVqeup2XqeQZcE1nXCE1EU0ILsIhgPGkjpRBtgFUodMlaeZHDFeMiFOiKTaoQKWDwDqSPG8gIzeYG1rg6vGYPjdKSZU2HkZBiE6qOC5NasSizU2eCk5UyECqHYrNOyMHEghpk3fzjO7fsmN5VhVnxHWuVqw3cIwQodYe1nweT6WunMvo30mOu_w
linkProvider Cold Spring Harbor Laboratory Press
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LS8NAEF7EInrziW9X0JOkbN7dg6dqqY8WQYXe4j4mJSCJtKnWP-VvdCZNRdCDF2-BbEIyuzPz7ezMN4ydAGIOQtKOaGlwgkCCI2NfOlp7RmmrW6CpdrjXj7qPwfUgHCywj3ktDKVV6qwYTbPX6hyfErbR-s6UW7i0Vw8qws2oiVAY3WuTwtR1UuUNvL_hlm18fnWB83vqeZ3Lh3bXqbsKONqNQukAYQQjPY2OLRYAaWh16vpapr5vwDWxdY3QxMoktACL7t6XNlYKXTNYlVIAFE1-g4jVSIs6g-ZXTMeT6BzjoD48_fVzEWbXv_fD-FcerbPKGnfqBUZrbAHydbY0a0n5vsGmc06nfMiVmZTAK8bLsphmBgE7L1Le7t_zb2VbvHjOhkVOvMhFmVkYc4rt0ghOyUo08dVTyjvjKre8N8SLLK8GEGKu-4dtssd_keMWW8yLHLYZF5FA-29ShfAEEUMoA9y1xrhW3NAaV0c77LgWWvIy4-BISLAJpeRFyUywOGYuzgQ1hI49VA7FZJyQVWsJ6sq1-4f3HLHl7kPvNrm96t_ssRW6X2WGtfbZYjmawAFikFIfVhPP2dN_r7RPKr7s-g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1JS8NAFB5EUby54u4IepKUyd45eLIW1yKo0Fuc5aUEJCltqu3f8hf6XpqKoAcvvQUyCcmbmfd981bGTgE5BzFpRzQ1OEEgwZGxLx2tPaO01U3QlDv80ImuX4LbbthdYJ-zXBgKq9RZMRhn75UfnwK2UftON7dw6aweVAU3owZSYYTXBpmpG32b1oGVdzD5wGPb8OKmhXN85nntq-fLa6fuLOBoNwqlA8QTjPQ0glssANLQ6tT1tUx934BrYusaoakyk9ACLEK-L22sFMIzWJWSERTV_hKu5YDaRbS7jW-7jicRIOOgdqD--clItetf_AUAFaq119jSo-rDYJ0tQL7BlqdtKSebbDyr65T3uDKjEnhV9bIsxplB0s6LlF92nviP1C1evGW9IqfayEWZWRhysu_SCE4BSzT51VPKO-cqt_yhhxdZXg0g1lz3ENtiL3OR4zZbzIscdhgXkUAMMKlCioKsIZQBnlxjXC9uaI2ro112Ugst6U_rcCQk2ITC8qJkKlgcMxNngruEXB8qh2I0TEizNQV15tr7x3uO2cpjq53c33Tu9tkq3a6Cw5oHbLEcjOAQaUipj6p55-x13gvtC68N7gI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preventing+acute+neurotoxicity+of+CNS+therapeutic+oligonucleotides+with+the+addition+of+Ca2%2B+and+Mg2%2B+in+the+formulation&rft.jtitle=bioRxiv&rft.au=Miller%2C+Rachael&rft.au=Paquette%2C+Joseph&rft.au=Barker%2C+Alexandra&rft.au=Sapp%2C+Ellen&rft.date=2024-06-08&rft.issn=2692-8205&rft.eissn=2692-8205&rft_id=info:doi/10.1101%2F2024.06.06.597639&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2692-8205&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2692-8205&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2692-8205&client=summon